{"id":"mdr-001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"null","effect":"Increased urination"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, MDR-001 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. MDR-001's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.","oneSentence":"MDR-001 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:48.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT07274137","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）","status":"NOT_YET_RECRUITING","sponsor":"MindRank AI Ltd","startDate":"2026-02","conditions":"Overweight or Obesity","enrollment":738},{"nctId":"NCT07110766","phase":"PHASE1","title":"Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight","status":"NOT_YET_RECRUITING","sponsor":"MindRank AI Ltd","startDate":"2025-08-09","conditions":"Obesity &Amp; Overweight","enrollment":24},{"nctId":"NCT06778850","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants","status":"RECRUITING","sponsor":"MindRank AI Ltd","startDate":"2023-06-09","conditions":"Overweight and Obese Volunteers","enrollment":131},{"nctId":"NCT06606483","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight","status":"NOT_YET_RECRUITING","sponsor":"MindRank AI Ltd","startDate":"2024-09-23","conditions":"Obesity, Overweight and Obesity","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MDR-001","genericName":"MDR-001","companyName":"MindRank AI Ltd","companyId":"mindrank-ai-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MDR-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}